These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18621566)

  • 21. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
    Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
    Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LRRK2 G2019S in the North African population: a review.
    Benamer HT; de Silva R
    Eur Neurol; 2010; 63(6):321-5. PubMed ID: 20413974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease.
    Patra B; Parsian AJ; Racette BA; Zhao JH; Perlmutter JS; Parsian A
    Parkinsonism Relat Disord; 2009 Mar; 15(3):175-80. PubMed ID: 18752982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients.
    Tan EK; Shen H; Tan LC; Farrer M; Yew K; Chua E; Jamora RD; Puvan K; Puong KY; Zhao Y; Pavanni R; Wong MC; Yih Y; Skipper L; Liu JJ
    Neurosci Lett; 2005 Aug; 384(3):327-9. PubMed ID: 15955629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical heterogeneity of the LRRK2 G2019S mutation.
    Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
    Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical features of LRRK2-associated Parkinson's disease].
    Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease.
    Marongiu R; Ghezzi D; Ialongo T; Soleti F; Elia A; Cavone S; Albanese A; Altavista MC; Barone P; Brusa L; Cortelli P; Petrozzi L; Scaglione C; Stanzione P; Tinazzi M; Zeviani M; Dallapiccola B; Bentivoglio AR; Valente EM; Garavaglia B;
    Mov Disord; 2006 Aug; 21(8):1232-5. PubMed ID: 16622859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
    J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study of LRRK2 mutations and Parkinson's disease in Brazil.
    Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
    Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease.
    Yescas P; López M; Monroy N; Boll MC; Rodríguez-Violante M; Rodríguez U; Ochoa A; Alonso ME
    Neurosci Lett; 2010 Nov; 485(2):79-82. PubMed ID: 20727385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease.
    Funalot B; Nichols WC; Pérez-Tur J; Mercier G; Lucotte G
    Genet Test; 2006; 10(4):290-3. PubMed ID: 17253937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
    Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
    Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.
    Ishihara L; Gibson RA; Warren L; Amouri R; Lyons K; Wielinski C; Hunter C; Swartz JE; Elango R; Akkari PA; Leppert D; Surh L; Reeves KH; Thomas S; Ragone L; Hattori N; Pahwa R; Jankovic J; Nance M; Freeman A; Gouider-Khouja N; Kefi M; Zouari M; Ben Sassi S; Ben Yahmed S; El Euch-Fayeche G; Middleton L; Burn DJ; Watts RL; Hentati F
    Mov Disord; 2007 Jan; 22(1):55-61. PubMed ID: 17115391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
    Bras JM; Guerreiro RJ; Ribeiro MH; Januario C; Morgadinho A; Oliveira CR; Cunha L; Hardy J; Singleton A
    Mov Disord; 2005 Dec; 20(12):1653-5. PubMed ID: 16149095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant.
    Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB
    Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
    Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease.
    Infante J; Rodríguez E; Combarros O; Mateo I; Fontalba A; Pascual J; Oterino A; Polo JM; Leno C; Berciano J
    Neurosci Lett; 2006 Mar; 395(3):224-6. PubMed ID: 16298482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.